About US
Contact us
-
Shire could use boost from adult ADHD med to hit $10B goalShire ($SHPG) has said it's targeting $10 billion in sales by 2020, with $3 billion of that coming from its current pipeline. Now, it looks like anADHDproduct waiting in the wings could be ready in ti2015/4/8
-
Shire's Lialda, Gattex are hedge funder's latest patent targetsHedge fund manager Kyle Bass has struck out at drug patents once again. Just weeks after challenging two patents on an Acorda Therapeutics ($ACOR) drug, Bass asked the U.S. Patent and Trademark Office2015/4/7
-
J&J, Novartis lead pharma companies by market capWhich Big Pharma companies have the biggest market caps in the industry? TheMotley Foolhas a breakdown of the top 10, but we'll give you a hint: The list begins with Johnson & Johnson ($JNJ) and N2015/4/7
-
GSK shingles shot might trump Merck's Zostavax, analysts sayThough GlaxoSmithKline ($GSK) is still waiting on late-stage results from itsshinglesvaccine, HZ/su, Cowen & Co. analysts say the GSK shot may just be better than Merck'sZostavax. The deciding fac2015/4/3
-
Pfizer shutters vaccine sales business in China after Prevenar setbackAs it beefs up its vaccines business, Pfizer's ($PFE) looking to bolster revenue from the top-sellingPrevenarfamily of shots. But on that front, it's come up against a roadblock inChina--and so it's s2015/4/3
-
Celltrion revs up Remicade biosim for U.S. rollout this yearWatch out,Remicade. South Korea-basedCelltrionis gunning to launch its biosimilar version,Remsima, in the U.S. by the end of this year. In an interview withThe Wall Street Journal, Celltrion CEO Stan2015/4/2
-
UCB hands over South Asia branded drugs to Dr. Reddy's in latest slimdown planBelgium'sUCBis slimming down, selling some of its branded products in South Asia toDr. Reddy's Laboratoriesfor $128.38 million to focus on its neurology portfolio in India. The deal hands Dr. Reddy's2015/4/2
-
Heavyweight PBMs mean trouble for Big Pharma's pricey new medsThe good news for drugmakers, after UnitedHealth ($UNH) agreed to buy Catamaran ($CTRX): You might need fewer staffers to negotiate with pharmacy benefits managers, now that 1 billion U.S. scripts a y2015/4/1
-
Indian pharma exec: Compulsory licensing cost us $10B in investmentIndia-based Hetero Pharma's director adopted a heretical position in the local pharmaceutical industry when he said use of the compulsory licensing process has costIndia$10 billion in potential invest2015/4/1
-
Gilead's huge Sovaldi payoff yields a nice 23% pay hike for CEONo one would say Gilead Sciences CEOJohn Martinis hurting financially. For several years, he has collected annual compensation worth about $15 million. Not too shabby. And his stock gains since 2009 r2015/3/31